| Metric | FY2025 | FY2024 | FY2024 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $185.7M-28.3% | $259.2M+275.5% | $69.0M-0.6% | $69.4M-76.0% | $288.9M | — | $799.2M+181.3% | $284.1M+98.5% | $143.1M |
| Cost of revenue | $151.8M+0.6% | $150.9M+310.1% | $36.8M-4.6% | $38.6M-74.1% | $148.7M | — | $140.6M+76.5% | $79.6M+19.1% | $66.8M |
| Gross profit | $34.0M-68.6% | $108.3M | — | — | $140.2M | — | — | — | — |
| Selling, general and administrative | $145.1M-10.3% | $161.8M+313.9% | $39.1M-3.6% | $40.6M-73.2% | $151.4M | — | $100.1M+6.2% | $94.2M+94.9% | $48.4M |
| Research and development | $17.4M-9.5% | $19.2M+308.6% | $4.7M-4.5% | $4.9M-71.5% | $17.3M | — | $15.2M+63.6% | $9.3M+156.5% | $3.6M |
| Change in estimated fair value of contingent consideration | $200K+110.0% | -$2.0M-1025.3% | -$178K+85.1% | -$1.2M+63.6% | -$3.3M | — | $0 | $0-100.0% | $322K |
| Impairment of goodwill and long-lived assets | $68.7M-58.6% | $166.2M | — | — | $0 | — | — | — | — |
| Restructuring | $17.8M+1568.5% | -$1.2M-30250.0% | -$4K+0.0% | -$4K-100.1% | $6.5M | — | $0 | — | — |
| Total operating expenses | $249.3M-27.5% | $343.9M+46.6% | $234.6M+183.2% | $82.9M-51.8% | $171.8M | — | $244.6M+49.0% | $164.2M+37.8% | $119.2M |
| Loss from operations | -$215.3M+8.6% | -$235.6M-42.3% | -$165.6M-1132.2% | -$13.4M+57.5% | -$31.6M | — | $554.6M+362.6% | $119.9M+399.8% | $24.0M |
| Interest expense | -$27.0M+43.4% | -$47.7M-249.9% | -$13.6M-14.2% | -$11.9M+74.0% | -$45.9M | — | -$30.3M+1.6% | -$30.7M-2.6% | -$30.0M |
| Interest income | $11.4M-58.3% | $27.4M+287.5% | $7.1M-0.2% | $7.1M-74.4% | $27.7M | — | $0 | $0 | — |
| Loss on extinguishment of debt | $0+100.0% | -$3.2M+0.0% | -$3.2M | $0 | $0 | — | $0+100.0% | -$7.6M | $0 |
| Change in payable to related parties pursuant to the Tax Receivable Agreement | $0+100.0% | -$40K-2.6% | -$39K+0.0% | -$39K-100.0% | $668.9M | — | $6.1M | $0 | $0 |
| Other expense | -$4.2M-77.4% | -$2.3M-3351.4% | $72K+102.8% | -$2.6M-91.6% | -$1.3M | — | $279K+121.4% | $126K+6.8% | $118K |
| (Loss) income before income taxes | -$235.0M+10.1% | -$261.5M-51.9% | -$172.1M-725.4% | -$20.9M-103.4% | $617.7M | — | $530.8M+549.7% | $81.7M+1495.8% | -$5.9M |
| Income tax (benefit) expense | -$4.2M-126.5% | -$1.9M-698.1% | $311K+112.8% | -$2.4M-100.3% | $756.1M | — | $61.5M+2035.9% | $2.9M+541.7% | -$652K |
| Net loss | -$230.8M+11.1% | -$259.6M-50.5% | -$172.5M-836.2% | -$18.4M+86.7% | -$138.4M | — | $469.3M+495.4% | $78.8M+1615.4% | -$5.2M |
| Net loss attributable to non-controlling interests | -$100.0M+12.9% | -$114.8M-52.3% | -$75.4M-773.4% | -$8.6M+55.4% | -$19.3M | — | $287.2M+2928.0% | -$10.2M-1289.3% | -$731K |
| Net loss attributable to Maravai LifeSciences Holdings, Inc. | -$130.8M+9.7% | -$144.8M-49.2% | -$97.1M-891.7% | -$9.8M+91.8% | -$119.0M | — | $182.0M+104.6% | $89.0M+2090.4% | -$4.5M |
| Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share) | -$900.00+14.3% | -$1050.00-54.4% | -$680.00-871.4% | -$70.00+92.2% | -$900.00 | — | $1590.00-78.6% | $7430.00+24866.7% | -$30.00 |
| Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share) | -$900.00+14.3% | -$1050.00-54.4% | -$680.00-871.4% | -$70.00+92.2% | -$900.00 | — | $1560.00-33.9% | $2360.00+7966.7% | -$30.00 |
| Weighted average Class A common shares outstanding—basic (in shares) | 144.4M+4.7% | 137.9M-2.6% | 141.6M+4.2% | 135.8M+3.0% | 131.9M | — | 114.8M+1009.0% | 10.4M-100.0% | 253.92B |
| Weighted average Class A common shares outstanding - diluted (in shares) | 144.4M+4.7% | 137.9M-2.6% | 141.6M+4.2% | 135.8M+3.0% | 131.9M | — | 257.8M+791.8% | 28.9M-100.0% | 253.92B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.